Xofigo may face additional commercial threats from the recently approved targeted radioligand therapy Lu-177-PSMA-617 (Pluvicto), which has the potential for utility in a broader population of metastatic prostate cancer patients; unlike Xofigo, Lu-177-PSMA-617 use is not restricted to patients with metastases predominantly in bone. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.